8B6M image
Deposition Date 2022-09-27
Release Date 2023-10-11
Last Version Date 2025-04-30
Entry Detail
PDB ID:
8B6M
Keywords:
Title:
Tankyrase 2 in complex with an inhibitor
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.60 Å
R-Value Free:
0.21
R-Value Work:
0.18
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Poly [ADP-ribose] polymerase tankyrase-2
Gene (Uniprot):TNKS2
Chain IDs:A, C
Chain Length:171
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Poly [ADP-ribose] polymerase tankyrase-2
Gene (Uniprot):TNKS2
Chain IDs:B, D
Chain Length:48
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization.
J.Med.Chem. 68 7263 7279 (2025)
PMID: 40134122 DOI: 10.1021/acs.jmedchem.4c02845

Abstact

Designing inhibitors is a complex task that requires a deep understanding of protein-ligand interactions and their dynamics. Ligands often interact with multiple binding subsites, with noncovalent interactions affecting binding affinity. Conformational changes and plasticity of both, the ligand and the protein influence binding energetics. We investigated the tankyrase ADP-ribosyltransferase as a promising drug target regulating many cellular pathways. Despite the existence of diverse tankyrase inhibitors, their binding energetics and contributions of flexible cryptic subpockets to binding affinity remain elusive. To examine these aspects, we deconstructed inhibitors to key fragments, dissected their energetic contribution to the affinity, and determined their binding mode by X-ray crystallography. Varying ligand efficiencies of the deconstructed, pocket-binding fragments revealed the cryptic nature of subpockets. These insights enabled us to redesign inhibitors with novel linkers, the observed key area for optimization, increasing the potency in enzymatic and cell-based assays by 7.5-fold and 6.2-fold compared to the parent ligand.

Legend

Protein

Chemical

Disease

Primary Citation of related structures